Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2733598 | 1.00 | MGLL (0.36) | MGLLPIK3R1PIK3CARORCGPR119 | |
| SCHEMBL2713151 | 0.77 | GPR119 (0.49) | MGLLPIK3CARORCGPR119USP2 | |
| SCHEMBL9951786 | 0.77 | GPR119 (0.49) | MGLLPIK3CARORCGPR119USP2 | |
| SCHEMBL2727269 | 0.75 | GPR119 (0.55) | RORCGPR119LMNA | |
| SCHEMBL2728583 | 0.75 | GPR119 (0.47) | MGLLRORCGPR119MEN1KMT2A | |
| SCHEMBL10132382 | 0.74 | GPR119 (0.46) | MGLLRORCGPR119HPGDLMNA | |
| SCHEMBL2712292 | 0.72 | GPR119 (0.45) | MGLLRORCGPR119LMNA | |
| SCHEMBL2727935 | 0.71 | GPR119 (0.47) | MGLLRORCGPR119LMNA | |
| SCHEMBL2733601 | 0.71 | MGLL (0.37) | MGLLRORC | |
| SCHEMBL23752795 | 0.70 | MGLL (0.54) | MGLLRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| EP-2445887-A2 | NOVEL AZABICYCLOHEXANES | Panacea Biotec Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010150281-A2 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | MGLL 4807/4885PIK3R1 2317/4885PIK3CA 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.